News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
473,507 Results
Type
Article (28874)
Company Profile (317)
Press Release (444307)
Multimedia
Podcasts (103)
Webinars (16)
Section
Business (126501)
Career Advice (312)
Deals (21228)
Drug Delivery (71)
Drug Development (64518)
Employer Resources (45)
FDA (9165)
Job Trends (7359)
News (219176)
Policy (17102)
Tag
2027 BioMidwest Elite (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (1365)
Accelerated approval (38)
Adcomms (15)
Allergies (145)
Alliances (35477)
ALS (184)
Alzheimer's disease (1328)
Antibody-drug conjugate (ADC) (432)
Approvals (9577)
Artificial intelligence (497)
Autoimmune disease (299)
Automation (33)
Bankruptcy (166)
Best Places to Work (6202)
BIOSECURE Act (6)
Biosimilars (153)
Biotechnology (240)
Bladder cancer (184)
Brain cancer (66)
Breast cancer (623)
Cancer (5129)
Cardiovascular disease (392)
Career advice (278)
Career pathing (11)
CAR-T (322)
CDC (17)
Celiac Disease (2)
Cell therapy (841)
Cervical cancer (29)
Clinical research (56571)
Collaboration (1795)
Company closure (3)
Compensation (1029)
Complete response letters (69)
COVID-19 (2306)
CRISPR (110)
C-suite (949)
Cystic fibrosis (143)
Data (7043)
Decentralized trials (1)
Denatured (21)
Depression (139)
Dermatology (75)
Diabetes (396)
Diagnostics (3304)
Digital health (33)
Diversity (6)
Diversity, equity & inclusion (13)
Drug discovery (291)
Drug pricing (83)
Drug shortages (10)
Duchenne muscular dystrophy (278)
Earnings (45572)
Editorial (39)
Employer branding (6)
Employer resources (44)
Events (85811)
Executive appointments (909)
FDA (12140)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (17)
Frontotemporal dementia (32)
Funding (1502)
Gene editing (238)
Generative AI (36)
Gene therapy (674)
GLP-1 (719)
Government (2136)
Grass and pollen (7)
Guidances (306)
Healthcare (9290)
HIV (67)
Huntington's disease (53)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (98)
Immunology and inflammation (269)
Immuno-oncology (86)
Indications (170)
Infectious disease (2562)
Inflammatory bowel disease (206)
Inflation Reduction Act (12)
Influenza (105)
Intellectual property (241)
Interviews (48)
IPO (9806)
IRA (18)
Job creations (1557)
Job search strategy (242)
JPM (50)
Kidney cancer (14)
Labor market (35)
Layoffs (307)
Leadership (14)
Legal (3396)
Liver cancer (73)
Longevity (27)
Lung cancer (688)
Lymphoma (415)
Machine learning (41)
Management (11)
Manufacturing (723)
MASH (186)
Medical device (4992)
Medtech (5046)
Mergers & acquisitions (12425)
Metabolic disorders (1117)
mRNA (193)
Multiple sclerosis (160)
NASH (17)
Neurodegenerative disease (364)
Neuropsychiatric disorders (95)
Neuroscience (2654)
Neurotech (1)
NextGen: Class of 2026 (2883)
Non-profit (1333)
Now hiring (40)
Obesity (500)
Opinion (221)
Ovarian cancer (211)
Pain (184)
Pancreatic cancer (271)
Parkinson's disease (339)
Partnered (19)
Patents (463)
Patient recruitment (605)
Peanut (55)
People (46845)
Pharmaceutical (46)
Pharmacy benefit managers (15)
Phase 1 (18937)
Phase 2 (25833)
Phase 3 (17432)
Pipeline (7449)
Policy (140)
Postmarket research (1501)
Preclinical (7878)
Press Release (40)
Prostate cancer (256)
Psychedelics (58)
Radiopharmaceuticals (292)
Rare diseases (986)
Real estate (2844)
Recruiting (20)
Regulatory (15643)
Reports (23)
Research institute (1348)
Resumes & cover letters (39)
Rett syndrome (35)
RNA editing (27)
RSV (60)
Schizophrenia (159)
Series A (262)
Series B (228)
Service/supplier (2)
Sickle cell disease (107)
Special edition (21)
Spinal muscular atrophy (141)
Sponsored (26)
Startups (3054)
State (1)
Stomach cancer (9)
Supply chain (71)
Tariffs (38)
The Weekly (80)
Vaccines (758)
Venture capital (95)
Weight loss (283)
Women's health (79)
Worklife (2)
Date
Today (99)
Last 7 days (621)
Last 30 days (2819)
Last 365 days (24347)
2026 (10194)
2025 (24627)
2024 (25863)
2023 (27428)
2022 (35026)
2021 (38114)
2020 (33280)
2019 (21715)
2018 (16093)
2017 (22102)
2016 (22758)
2015 (28106)
2014 (21392)
2013 (17607)
2012 (18078)
2011 (17822)
2010 (16311)
Location
Africa (380)
Alabama (79)
Alaska (2)
Arizona (157)
Arkansas (12)
Asia (29509)
Australia (4830)
California (11061)
Canada (2829)
China (1158)
Colorado (411)
Connecticut (499)
Delaware (389)
Europe (68112)
Florida (1457)
Georgia (326)
Hawaii (3)
Idaho (29)
Illinois (839)
India (64)
Indiana (303)
Iowa (15)
Japan (452)
Kansas (104)
Kentucky (27)
Louisiana (24)
Maine (16)
Maryland (1164)
Massachusetts (8191)
Michigan (198)
Minnesota (428)
Mississippi (3)
Missouri (87)
Montana (18)
Nebraska (9)
Nevada (104)
New Hampshire (38)
New Jersey (2913)
New Mexico (16)
New York (2846)
North Carolina (1251)
North Dakota (9)
Northern California (5528)
Ohio (295)
Oklahoma (13)
Oregon (29)
Pennsylvania (1924)
Puerto Rico (15)
Rhode Island (32)
South America (657)
South Carolina (18)
Southern California (4421)
Tennessee (94)
Texas (1624)
United States (37139)
Utah (185)
Virginia (269)
Washington D.C. (52)
Washington State (851)
West Virginia (2)
Wisconsin (128)
Wyoming (1)
473,507 Results for "amarna therapeutics b v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials for Type 1 Diabetes
July 9, 2025
·
5 min read
Press Releases
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
April 9, 2026
·
2 min read
Business
Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Type 1 Diabetes Mellitus, announces the appointment of Aurelia Caparrós as the Company’s new Chief Business Officer, effective 1st of April 2024.
April 19, 2024
·
3 min read
Press Releases
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
April 23, 2026
·
19 min read
Business
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
Amarna Therapeutics, a privately-held biotechnology company focused on developing transformative gene therapies for a range of rare and prevalent genetic diseases, including Type 1 Diabetes Mellitus, is pleased to announce the formation of its new Scientific Advisory Board. The newly established SAB consists of seven distinguished international scientific opinion leaders.
June 17, 2024
·
7 min read
Press Releases
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
December 4, 2024
·
5 min read
Press Releases
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
April 15, 2026
·
3 min read
Press Releases
Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments
April 21, 2026
·
3 min read
Immunology and inflammation
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+
Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders.
March 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Nocion Therapeutics Announces Full Enrollment in Phase 2b ASPIRE Study of Taplucainium for Chronic Cough
May 5, 2026
·
3 min read
1 of 47,351
Next
